Observational cohort study of rilpivirine (RPV) utilization in Europe
Journal: AIDS Research and Therapy
Year: 2022

Our estimates of VF > 50 copies/mL and resistance in participants treated with RPV were similar to those reported by other studies. RPV safety profile was favourable with less frequent discontinuation due to toxicity than EFV (especially for CNS).